Response to Plöderl et al. re: “A Multicenter Double-Blind,Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder”
Restricted accessLetterFirst published online March, 2024
Response to Plöderl et al. re: “A Multicenter Double-Blind,Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder”
BaumelWT, MillsJA, SchroederHK, et al.Gastrointestinal symptoms in pediatric patients with anxiety disorders and their relationship to selective serotonin reuptake inhibitor treatment or placebo. Child Psychiatry Hum Dev, 2023; doi: 10.1007/s10578-023-01586-x.
2.
DobsonET, StrawnJR. Placebo response in pediatric anxiety disorders: Implications for clinical trial design and interpretation. J Child Adolesc Psychopharmacol, 2016; 26(8):686–693; doi: 10.1089/cap.2015.0192.
3.
MillsJA, StrawnJR. Antidepressant tolerability in pediatric anxiety and obsessive-compulsive disorders: A Bayesian hierarchical modeling meta-analysis. J Am Acad Child Adolesc Psychiatry, 2020; 59(11):1240–1251; doi: 10.1016/j.jaac.2019.10.013.
4.
PlöderlM, HorowitzMA, HengartnerMP. Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder. J Child Adolesc Psychopharmacol, 2023; 33(7):295–296; doi: 10.1089/cap.2023.0029.
5.
StrawnJR, MillsJA, SchroederH, et al.Escitalopram in adolescents with generalized anxiety disorder: A double-blind, randomized, placebo-controlled study. J Clin Psychiatry, 2020; 81(5):20m13396; doi: 10.4088/JCP.20m13396.
6.
StrawnJR, MoldauerL, HahnRD, et al.A multicenter double-blind, placebo-controlled trial of escitalopram in children and adolescents with generalized anxiety disorder. J Child Adolesc Psychopharmacol, 2023; 33(3):91–100; doi: 10.1089/cap.2023.0004.
